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Abstract
Fast and reliable assays to precisely define the nature of the infectious agents causing sepsis are eagerly anticipated. New
molecular biology techniques are now available to define the presence of bacterial or fungal DNA within the bloodstream of
sepsis patients. We have used a new technique (VYOOH) that allows the enrichment of microbial DNA before a multiplex
polymerase chain reaction (PCR) for pathogen detection provided by SIRS-Lab (Jena, Germany). We analyzed 72 sepsis
patients and 14 non-infectious systemic inflammatory response syndrome (SIRS) patients. Among the sepsis patients, 20
had a positive blood culture and 35 had a positive microbiology in other biological samples. Of these, 51.4% were positive
using the VYOOH test. Among the sepsis patients with a negative microbiology and the non-infectious SIRS, 29.4% and
14.2% were positive with the VYOOH test, respectively. The concordance in bacterial identification between microbiology
and the VYOOH test was 46.2%. This study demonstrates that these new technologies offer great hopes, but improvements
are still needed.
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Introduction
Sepsis is a common cause of morbidity and death in intensive
care units [1–3]. The diagnosis of sepsis is difficult, because
clinical signs of sepsis often overlap with other non-infectious
causes of systemic inflammation. These signs include tachycardia,
leukocytosis, tachypnea, and pyrexia, which are collectively
termed a systemic inflammatory response syndrome (SIRS).
SIRS is very common in critically ill patients, being found in
various conditions including trauma, surgery, burns, pancreatitis,
post-cardiac arrest syndrome, cardiac surgery (particularly those
requiring extracorporeal circulation) and hypoxic injuries [4–6].
This means these signs can be misleading as critically ill patients
often display a SIRS without infection [7–10]. Microbiological
culture can be used to distinguish sepsis from non-infectious
conditions. However, blood culture lacks sensitivity, and there is
often a substantial time delay. This issue is of paramount
importance, since therapy and outcome differ greatly between
SIRS patients with or without infection. Clinicians are often
prone to overuse antibiotic therapy, for fear of not treating a
potential infection or superinfection, however, the widespread use
of antibiotics for all such patients is likely to increase antibiotic
resistance, toxicity, and costs [11]. On the other hand, any delay
in administration of antibiotics can be extremely detrimental for
a severely ill infected patient with an exponential increase in the
odds ratio for death [12,13]. The search for early biomarker
tools for the diagnosis of infection, such as procalcitonin (PCT)
and soluble Triggering receptor expressed on myeloid cells-1
(sTREM-1), initially yielded promising results in discriminating
sepsis from aseptic SIRS. However, these results have been
widely challenged and are now considered controversial because
they seem more related to the inflammatory response, irrespec-
tive of the cause [14,15]. Furthermore up to 40% of the
infections remain strongly suspected but not bacteriologically
documented [3,16].
Research is ongoing to find new markers, profiles or combina-
tions of markers to better discriminate SIRS related to infection
from SIRS unrelated to infection. Many biomarkers have been
under scrutiny such as copeptin [17], proendothelin-1 [18],
proadrenomedullin [19] identified by proteome analysis. Cytokine
profiles using multiplex analysis seem more related to the severity
of the SIRS than the trigger of the SIRS (infectious or non-
infectious diseases) [20]. Thus, new tools have been developed to
identify bacteria by detecting their DNA using various techniques
such as hybridization probe assays and real time polymerase chain
reaction (PCR). These techniques have many potential interests
over conventional microbiological tests including: decreased
delivery time (within approximately 2–8 hours), reduced risk of
negative culture due to prior use of antibiotics, detection of slow or
fastidiously growing organisms and discrimination between non-
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antibiotics. However, these tests remain to be validated in a
clinical setting.
The goal of the current study was to evaluate the diagnostic
value of a number of biomarkers that may help to distinguish
infectious from non-infectious SIRS and possibly identify the
causative pathogen by plasma detection of microbial DNA, in
intensive care unit (ICU) patients with a (clinically) suspected
bacterial infection.
Results
Patients
We planned to include a first cohort of patients and then if the
results had been highly positive to include 300 more patients as a
confirmatory cohort. Based on the results reported in this first
cohort, we decided not to further pursue the study. We included
83 patients with sepsis and 18 with non-infectious SIRS. Due to
insufficient amounts of DNA recovered after the LooxsterH step,
contamination or missing tubes, only 72 patients with sepsis and
14 non-infectious SIRS could be analyzed.
The majority of sepsis patients were male (62.55%). The median
age of patients was 73 years {55–80} and median SAPS II score
and SOFA score at admission were 50 {34–65} and 7 {5–11}
respectively. Fifty seven percent of the patients required vasoactive
or inotrope support at inclusion. The infection was located in the
lungs (53%), abdomen (23%), urinary tract (14%), or other sites
and multi-site (13%). The infection was community-acquired for
60% cases, hospital-acquired for 27% cases and ICU-acquired for
13% cases. Seventeen sepsis patients had no positive microbio-
logical samples. ICU mortality was 29.7% among sepsis patients
and 28.5% among SIRS patients (table 1).
Amongst the non-infectious SIRS, 64% were male. The median
age of patients was 70 years {67–83} and median SAPS II score
and SOFA score at admission were 46 {42–65} and 8 {5–9}
respectively. One patient had a successfully resuscitated cardiac
arrest, 1 had hemorrhagic shock, 2 had severe cardiogenic shock
requiring inotropes or vasoactive agents, and 10 were post-
operative cardiac surgery patients requiring extracorporeal circu-
lation (the latter requiring vasoactive support in 9 cases).
Blood Cultures and VYOOH Analysis
Twenty sepsis patients had a positive blood culture and 35 had
a positive culture in another biological sample (i.e. broncho-
alveolar lavages, urine, catheter, ascitis, peritoneal fluid, synovial
fluid, cerebrospinal fluid, bile, skin, or bone biopsies) (figure 1).
According to blood cultures and cultures of other biological
samples, infections were due to Gram-negative bacteria (14
cases), Gram-positive bacteria (20 cases), mixed Gram-negative
and Gram-positive bacteria (12 cases), anaerobes (2 cases), and
Candida spp (1 case). Five cases were displaying both fungal (4
Candida albicans,1C. lusitaniae) and bacterial infection in other
compartments thanblood, and 18 had no identified organism.
Microorganisms were detected in the blood of 37 out of 72
sepsis patients (51.4%) with the VYOOH technique and the results
were better amongst those with a positive blood culture: 14/20
(70%) were accurately detected (table 2). Interestingly, 9 patients
with identified organisms at the site of infection were correctly
detected with the VYOOH technique without concomitant
septicaemia. For two additional positive PCR in the septic cohort,
the microorganism detected was compatible with non-documented
sites of infection amongst these patients (Pneumonia/Streptococcus
pneumoniae and severe colitis/Morganella morganii). Two positive
VYOOH detections were obtained among the non-infectious SIRS
cohort (14,2%), neither of which had a documented infection
based on classical bacteriological tests. No fungal infections were
detected using the VYOOH technology while microbiology
revealed one positive blood culture (C. albicans) and positivity in
five other samples (1 peritonitis, 3 lung infections, 1 surgical site).
According to microbiology, 48% of the patients were infected with
Gram-negative bacteria, among whom 28% were revealed by the
VYOOH technology. Among the pathogens revealed by microbi-
ological analysis and the VYOOH technology, E. coli was the most
prominent Gram-negative bacteria (34,6% and 19,6% respective-
ly) (figure 2). Among Gram-positive-bacteria the frequency of
Staphylococcus aureus (incl. MRSA) was 22.7% according to
microbiological analysis and 30.8% according to the VYOOH
technology. The correspondence in bacterial identification be-
tween microbiology and the VYOOH technology was 46.2%
(figure 2).
Clinical and Biological Parameters
Univariate analysis showed that amongst the clinical and
biological parameters, only fluid balance and CRP were signifi-
cantly higher in sepsis. CRP was statistically significant after
multivariate analysis (OR: 2.78 {IC95%: 1.005–1.029}, p,10
–4).
All other variables did not discriminate between the two groups,
including inflammatory cytokines (TNF, IL-6, IL-8, MCP-1
(CCL2)), anti-inflammatory cytokines (IL-10 and IL-1 Ra), and
circulating peptidoglycan (Table 1), and there was a trend of
higher levels of pro-calcitonin (p=0.06) and IL-10 (p=0.07)
(Table 1).
Discussion
A diverse array of new experimental approaches are now
available for the detection and identification of bloodstream
infections, such as matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI-TOF MS) [21,22], or
pyrosequencing [23,24]. The most studied approach is multiplex
real-time PCR [25,26,27]. Despite the fact that this has been
reported as a promising technology, validations are still required
[28]. Among those systems already commercially available,
SeptifastH has been the most studied [29,30,31,32,33,34], however
results have been inconsistent (for review see [35]).
In our study, we used another available technique for
multiplex PCR that detects a predefined panel of the most
important sepsis pathogens by electrophoretic separation of
target-specific amplicons (VYOOH, SIRS lab, Jena, Germany)
associated with a specific enrichment of bacterial DNA. Only
two meeting abstracts [36,37] have been published, both in
2009, on bacterial and fungal detection with this particular
approach. Here we report the first study using this approach in
sepsis and non-infectious SIRS patient. In the cohort of patients
with an infection, 70% of patients with positive blood cultures
also gave a positive result using the VYOOH technique.
Interestingly, we also found a good concordance between the
PCR detection and the bacteriological results observed at the
site of infection in nine cases without bacteremia. Furthermore,
we found two PCR results to be compatible with pathogens
usually seen at the site of infection responsible for the sepsis in
patients without a documented bacterial infection. Overall these
results seem to be comparable to those published using
SeptifastH [29,38]. Furthermore, we did not find any data in
favor of bacterial translocation in non-infectious SIRS, as may
have been expected, particularly in the post cardiac surgery
subgroup. We were also unable to detect Candida as described
with this technique [37], and this is in accordance with a
Detection of Microbial DNA in Sepsis
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38916previous study using SeptifastH [32], even in cancer patients
who are heavily colonized by this pathogen [38]. The limited
capacity to detect fungal DNA may be due either to some
technical problems linked to the nature of the infectious agents,
the low presence of fungi within the blood stream, or the low
levels of fungal circulating DNA when fungi are present within
the tissues. Of note, we had very few fungal infections in our
cohort.
We also measured a number of clinical and biological
parameters as well as various markers and cytokines. Interestingly,
the severity or organ dysfunction scores were similar in both
groups and, after multivariate analysis only CRP was able to
discriminate infectious from non-infectious SIRS. We have
previously shown that PCT is not associated with infection after
correction for shock severity (fluid balance or levels of catechol-
amines’ administration). Similarly to what we have already
observed with endotoxins, we studied here the circulating
peptidoglycan and again did not find any difference between
infectious and non-infectious SIRS.
In conclusion, the VYOOH approach for detecting microbial
DNA is technically demanding, requiring around 8 hours of work.
Despite encouraging results, its accuracy needs to be improved as
we found a significant number of false positive results. Further-
more, some patients may be infected by several pathogens and it
would be dangerous not to consider those that are not detected by
the VYOOH test. A limitation of our study was a rather low
number of patients. Because of our results, in accordance with our
statistician, we decided not to perform the scheduled validation
cohort because there was a limited chance to prove something else.
A larger study would be required after improvement of the test.
We are at the beginning of new era of molecular diagnostics in
septic patients; the results are encouraging but their current
accuracy needs to be improved before they can be considered a
reliable tool for clinicians and patient care.
Materials and Methods
Study Protocol
The protocol has been approved by the ethical committee of
Pitie ´-Salpe ´trie `re Hospital, Paris (NCT00698919), and written
informed consent was obtained from either the patient or the next
of kin. All ICU patients older than 18 years old, with a SIRS,
severe sepsis or septic shock were included in this cohort study.
SIRS, Severe sepsis and septic shock were defined according to the
definition used by a panel of experts from the American College of
Chest Physicians/Society of Critical Care Medicine [16,39].
Three medico-surgical ICUs participated in this study (Delafon-
taine Hospital, 17 beds; Jacques Cartier Institute, 24 beds; and
Saint-Joseph Hospital, 12 beds).
Table 1. Patients’ characteristics and dosages (median {range}).
Variables Sepsis (n=72) Non-infectious SIRS (n=14) p
At admission
Age (years) 73 {55–80} 70 {67–83} 0.32
Male (%) 45 (62.5%} 9 (64%) 0.89
SAPSII, 50 {34–65} 46 {42–65} 0.70
SOFA score 7 {5–11} 8.5 {5–9} 0.54
At inclusion
SOFA Score 7 {5–11} 7 {4–11} 0.59
White blood cells (10
9/L) 15 {11–23} 14 {12–19} 0.80
Hemoglobin (g/dl) 10.4 {9–12.9} 11.3 {10.6–11.6} 0.18
Platelets (10
9/L) 216 {128–337} 119 {132–25} 0.87
Urea (mmol/L) 12.3 {7.1–19.1} 12 {8.6–13.5} 0.74
Creatinine (mmol/L) 114 {7.1–19.1} 152 {8.6–13.5} 0.06
Alanine transaminase (U/L) 34 {20–63} 34 {22–122} 0.54
Aspartate transaminase (U/L) 49 {27–71} 27 {21–130} 0.69
Norepinephrine and/or epinephrine (mg/h) 0 {0–2.8} 0 {0–2.1} 0.09
Positive balance (ml/day) 2875 {1365–4960} 1350 {500–2000} 0.01
ICU Mortality (%) 22 (30.5%) 4 (28.5%) 0.77
Lactate (mmole/L) 2 {1.5–3.3} 2.2 {1.8–3.4} 0.17
CRP (mg/L) 195 {110–286} 76 {22–110} ,10
–4
Pro-Calcitonin (ng/mL) 4.84 {1.4–17.2} 0.4 {0.16–14} 0.06
IL-1Ra (pg/mL) 297 {114–1208} 776 {139–7272} 0.22
IL-6 (pg/mL) 151 {82–384} 224 {28–337} 0.81
IL-8 (pg/mL) 124 {53–268} 182 {28–275} 0.79
IL-10 (pg/mL) 11 {4–20} 19 {12–42} 0.07
MCP-1 (pg/mL) 104 {41–289} 125 {76–362} 0.40
TNF (pg/mL) 22 {14–32} 26 {19–51} 0.13
Peptidoglycan (pg/mL) 50 {0–65} 20 {0–90.6} 0.84
doi:10.1371/journal.pone.0038916.t001
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initiation. The following information was recorded: age, sex,
admission category (medical, scheduled surgery, or unscheduled
surgery), origin (home, ward, or emergency room), McCabe score
[40] and ICU and hospital mortality. Illness severity was evaluated
on the first day in ICU using the Simplified Acute Physiology
Score (SAPS II) [41], and Sepsis-related Organ Failure Assessment
(SOFA) score [42]. Knaus scale definitions were used to record
preexisting chronic organ failures including respiratory, cardiac,
hepatic, renal, and immune system failure [43]. The presence or
absence of infection was documented according to the recently
updated standard definitions developed by the Centers for Disease
Control [44]. In addition, quantitative cultures of specimens
obtained by bronchoalveolar lavage, protected specimen brush,
protected plugged catheter [45], or tracheal aspiration were
required to diagnose ventilator-associated pneumonia. Communi-
ty-acquired infection was defined as infection manifesting before
or within 48 hours after hospital admission. Hospital-acquired
infection was infection manifesting at least 48 hours after hospital
admission but before ICU admission. ICU-acquired infection was
diagnosed at least 48 hours after ICU admission. We observed in
our database that 20 species represented more than 90% of the
infection, so we grouped the most important pathogens depending
of the place of acquisition because the others were too rare to be
specifically studied. Infection sites were categorized as follows:
pneumonia, peritonitis, urinary tract infection, exacerbation of
chronic obstructive pulmonary disease, catheter-related infection,
primary bacteremia (excluding untreated Staphylococcus epidermidis
bacteremia), miscellaneous sites (mediastinitis, prostatitis, osteo-
myelitis, and others), and multiple sites. Early appropriate
antimicrobial therapy was defined as effectiveness on the causative
agent of at least one of the empirically selected antimicrobials on
Figure 1. Microbiology analysis in sepsis and SIRS patients. A. Number of sepsis patients with positive blood culture, positive microbiology in
other compartments (BAL, urine, catheter, ascitis, peritoneal fluid, synovial fluid, cerebrospinal fluid, bile, skin and bone biopsies), and total number of
sepsis patients with a positive VYOOH test. B. Number of non-infectious SIRS patients with a positive VYOOH test. C. Number of sepsis patients with a
positive blood culture who had a positive VYOOH test. D. Number of sepsis patients who had a negative blood culture but had a positive
microbiology test in other compartments who had a positive VYOOH test. E. Number of sepsis patients without any positive microbiology test who
had a positive VYOOH test.
doi:10.1371/journal.pone.0038916.g001
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of antimicrobials was assessed based on the culture results and
known susceptibility of the organism to the antimicrobials used
and on antimicrobial susceptibility testing. For nonfermenting
Gram-negative bacilli, aminoglycoside monotherapy was consid-
ered inappropriate [46].
We determined three groups: 1) Patients with documented
infection 2) Patients without infection, and 3) Patients with
suspected infection but no documented bacterial infection. The
type and number of microbiological samples taken was at the
discretion of the clinician in charge of the patient. The presence
or absence of infection, the sites of infection and causative
pathogens, were determined by the medical staff of each unit
and crossed checked by external validation (CA, FP, MM).
Most of the VYOOH tests have been done on the first day of
the occurrence of SIRS or sepsis (community-, hospital- or
ICU-acquired).
Routine measurements of plasma levels of C-reactive protein
(CRP) and procalcitonin (PCT) were performed according to the
manufacturer’s instructions (LumitestH; Brahms Diagnostica,
Berlin, Germany).
Two blood samples (4.5 mL each) were collected from each
patient. The first whole blood extraction (the DNA samples were
kept at 280uC until analyzed). From the second sample the
plasma was separated from leukocytes and red blood cells using
collection tubes containing gel and dipotassium EDTA following
centrifugation (1500 g for 10 minutes at 4uC). The plasma was
stored at 280uC until analyzed. Blood collection was performed
following the first episode that met SIRS criteria, either at
Figure 2. Matching between microbiology and bacterial DNA analysis. Comparison of the bacterial identification by classical microbiological
analysis or by the VYOOH technology. White bars: identification by classical microbiology in any compartments; grey bars: identification by VYOOH
test in blood samples; black bars: matching between microbiology and VYOOH test.
doi:10.1371/journal.pone.0038916.g002
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surperinfection).
Bacterial and Fungal DNA Detection
The bacterial and Fungal DNA detection was performed using
the Multiplex PCR pathogen detection system VYOOH (SIRS-
Lab GmbH, Jena, Germany). VYOOH combines culture-inde-
pendent pathogen-derived nucleic acid concentration and multi-
plex PCR-based species detection. The multiplex PCR delivers
results within 8 hours and detects 34 bacterial and 6 fungal species
that cause life-threatening infections (Gram positive bacteria:
Streptococcus pneumoniae, S. pyogenes, S. sanguinis, S. agalactiae S.
dysgalactiae S. mutans, Enterococcus faecium, E. faecalis, Clostridium
perfringens, Staphylococcus aureus, S. epidermidis, S. saprophyticus, S.
haemolyticus, S. hominis; Gram-negative bacteria: Escherichia coli,
Pseudomonas aeruginosa, Klebsiella pneumoniae, K. oxytoca, Enterobacter
cloacae, E. aerogenes, Neisseria meningitidis, Morganella morganii, Proteus
mirabilis, Acinetobacter baumannii, Bacteroides fragilis, Serratia marcescens,
Burkholderia cepacia, Stenotrophomonas maltophilia, Prevotella buccae, P.
intermedia, P.melaninogenica; Fungi : Aspergillus fumigatus, Candida
albicans C. dubliniensis, C. glabrata, C. tropicalis, C. krusei, C. parapsilosis)
as well as the five most common resistance markers (methicillin
mecA, vancomycin vanA, vancomycin vanB, b-lactamase blaSHV, b-
lactamase blaCTX-M). In order to ensure the highest clinical
validity, the primer selection for the species and antibiotic
resistance markers were based on the results of international
studies of septic infections [47].
The pathogen cells present in 5 ml of whole blood were
disrupted mechanically using glass beads (0.1/2.5 mm in diame-
ter) and a lysis device (e. g. FastPrepH-24, MP Biomedicals, Solon,
OH, USA). After a proteolytic digestion step, total DNA was
isolated using a short spin column protocol. The total DNA was
dissolved in an appropriate buffer provided by the manufacturer
and applied to the LOOXSTERH spin column. LOOXSTERH
specifically concentrates the minute quantity of bacterial and
fungal DNA from the predominant human DNA. Total DNA was
applied to an affinity chromatography column with a matrix-
immobilized DNA binding protein that recognizes motifs within
the pathogen DNA. More than 90% of the human DNA
background was removed. This effect substantially increases the
sensitivity of the downstream multiplex PCR protocol and
simultaneously reduces the time-to-result. The concentrated
pathogen DNA was directly used for multiplex PCR. The
pathogen-specific amplicons generated by the PCR step were
visualized by gel electrophoresis and compared with VYOOH-
specific DNA length markers to identify the pathogens or
resistance markers present. An alternative amplicon attribution
was achieved by hybridization (AT
H system, Clondiag), which
ensures a higher degree of specificity and sensitivity according to
the manufacturer recommendations.
Cytokine Detection
Dosage assays of plasma cytokines (IL-6, IL-8, IL-10 IL-1 Ra,
MCP-1, and TNF? were performed by Bio-Plex Multiplex
Cytokine Assay (BioRad Lab., Hercules, CA).
Peptidoglycan Detection
Peptidoglycan presence was measured using the Silkworm
Larvae Plasma (SLP) Reagent set Kit (Wako Pure Chemical
Industries Co. Ltd., Osaka, Japan). This technique that detects
peptidoglycan from both Gram-positive and Gram-negative
bacteria has already been shown to be effective for peptidoglycan
detection in plasma from patients with sepsis [48]. Of note, none
of these results were taken into account for treating our patients
since the technique was not yet validated.
Statistical Analysis
Data were expressed as medians with the interquartile range.
Numerical variables were analyzed using a nonparametric analysis
of variance (Kruskal-Wallis test) followed by a Mann-Whitney U
test for comparisons between two groups. Categorical variables
were compared by the chi-square or Fisher’s exact test. Relations
between two continuous variables were analyzed using the
Spearman’s rank correlation test (Stata Inc., College Station, TX.).
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Table 2. Microbiology and VYOOH test in sepsis patients with positive blood culture.
Positive Blood Culture VYOOH test +
Staphylococcus aureus 23
Methicilin resistant Staphylococcus aureus 42
Pseudomonas aeruginosa 10
Streptococcus pneumoniae 33
Escherichia coli 64
Klebsiella pneumoniae 11
Enterobater chloacae + Acinetobacter baumanii (2 organisms in the same blood
culture)
10
Neisseria meningitidis 10
Streptococcus oralis + Candida albicans (2 organisms in the same blood culture) 1 0
Haemophilus influenzae 01
TOTAL 20 14
doi:10.1371/journal.pone.0038916.t002
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